Baird served as co-manager on the offering
AboutCoherus BioSciences, Inc. (“Coherus” or the “Company”) (NASDAQ:CHRS) recently completed a follow-on offering of 5,948,274 shares of common stock, including the full exercise of the over-allotment option. Coherus sold 5,172,413 shares of common stock at a price to the public of $14.50 per share and the over-allotment option was exercised for an additional 775,861 shares. Coherus intends to use the net proceeds from this offering to build the commercial team and infrastructure to support the launch of CHS-1701, to manufacture the inventory and other manufacturing related activities to support the launch and subsequent commercial supply of CHS-1701 after approval and for ongoing manufacturing, development and clinical trial activities related to CHS-0214, CHS-1420, CHS-3351, CHS-2020 and CHS-131. If there are any remaining net proceeds from this offering, the Company intends to use them for working capital and other general corporate purposes.
Coherus is a United States based integrated development and commercialization biologics company, focused on biosimilars. Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and expand patient access. The Company’s team is composed of industry veterans with expertise in process science, analytical characterization, protein production, sales & marketing and clinical-regulatory development. Coherus is advancing CHS-1701 (pegfilgrastim biosimilar) towards commercialization, and has completed Phase III clinical programs for two anti-TNF product candidates, CHS-1420 (adalimumab biosimilar) and CHS-0214 (etanercept biosimilar). Coherus is also developing an early stage pipeline of ophthalmology biosimilar product candidates. Coherus is headquartered in Redwood City, California.
CONTACT US TO LEARN MORE
- May 2018
- Coherus BioSciences, Inc.
- Target Location
- North America